OSR Health, Inc. (OSRHW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
Peers in industry
OSR Health, Inc. has no peer companies in this window.
Recent press releases
April 2026
OSRHW Amends Stock Purchase Agreement, Secures $1M Convertible Note
# 🧾 What This Document Is This is an 8-K filing, which companies use to announce major events to investors. This specific filing includes two key agreements (shown as Exhibits) with an investor called **White Lion Capital, LLC**. **In simple terms:** OSR Holdings is changing its deal with an exis
SEC filings
All filings →Insider trades
All insider trades →OSR Health, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at OSR Health, Inc.
All people →No officers or directors have been indexed for OSR Health, Inc..